血友病基因治疗走向成熟
本文综述重组腺相关病毒(rAAV)介导的血友病A和B基因转移的既往进展与当前临床试验研究。血友病基因治疗进展曾在美国血液学会三次科学全体会议上报告,包括1998年大型动物模型血友病B首次「治愈」、2011年首例人持续载体衍生凝血因子IX活性、2016年临床试验报告持续载体衍生凝血因子IX活性达到轻度或正常范围。综述指出基因治疗具有一次性改变疾病甚至治愈的潜力。
要点
- 1998年大型动物模型血友病B首次实现「治愈」。
- 2011年首例人持续载体衍生凝血因子IX活性。
- 2016年临床试验报告持续载体衍生凝血因子IX活性达到轻度或正常范围。
核心结论
- 基因治疗具有一次性改变疾病甚至治愈的独特潜力。
- 进展至临床有意义的成功,加上多项正在进行的rAAV介导血友病基因转移临床试验,提示改变血友病治疗模式的目标可能很快实现。
研究设计与样本
- 综述,聚焦rAAV介导的血友病A和B基因转移的既往进展与当前临床试验研究。
主要发现
- 1998年大型动物模型血友病B首次实现「治愈」。
- 2011年首例人持续载体衍生凝血因子IX活性。
- 2016年临床试验报告持续载体衍生凝血因子IX活性达到轻度或正常范围。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Concurrent with the development of recombinant factor replacement products, the characterization of the F9 and F8 genes over 3 decades ago allowed for the development of recombinant factor products and made the hemophilias a target disease for gene transfer. The progress of hemophilia gene therapy has been announced in 3 American Society of Hematology scientific plenary sessions, including the first "cure" in a large animal model of hemophilia B in 1998, first in human sustained vector-derived factor IX activity in 2011, and our clinical trial results reporting sustained vector-derived factor IX activity well into the mild or normal range in 2016. This progression to clinically meaningful success combined with numerous ongoing recombinant adeno-associated virus (rAAV)-mediated hemophilia gene transfer clinical trials suggest that the goal of gene therapy to alter the paradigm of hemophilia care may soon be realized. Although several novel therapeutics have recently emerged for hemophilia, gene therapy is unique in its potential for a one-time disease-altering, or even curative, treatment. This review will focus on the prior progress and current clinical trial investigation of rAAV-mediated gene transfer for hemophilia A and B.
引用
- George LA. Hemophilia gene therapy comes of age. Blood Adv. 2017. PMID: 29296912. doi:10.1182/bloodadvances.2017009878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。